Thompson Siegel & Walmsley LLC Decreases Position in Clarivate PLC $CLVT

Thompson Siegel & Walmsley LLC reduced its stake in Clarivate PLC (NYSE:CLVT) by 4.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,815,675 shares of the company’s stock after selling 479,587 shares during the period. Thompson Siegel & Walmsley LLC owned 1.48% of Clarivate worth $32,784,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CLVT. M&T Bank Corp purchased a new stake in Clarivate in the fourth quarter valued at approximately $34,000. Essex Financial Services Inc. purchased a new position in shares of Clarivate during the third quarter worth approximately $41,000. North Dakota State Investment Board acquired a new position in shares of Clarivate in the 4th quarter valued at $42,000. Beese Fulmer Investment Management Inc. acquired a new position in shares of Clarivate in the 4th quarter valued at $44,000. Finally, PharVision Advisers LLC purchased a new stake in Clarivate in the 3rd quarter valued at $45,000. 85.72% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CLVT has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Clarivate in a research note on Friday, March 27th. Barclays reduced their target price on shares of Clarivate from $4.00 to $2.40 and set an “underweight” rating for the company in a report on Wednesday, February 25th. Wall Street Zen upgraded shares of Clarivate from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Royal Bank Of Canada lowered their price target on Clarivate from $5.00 to $3.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 25th. Finally, Citigroup dropped their price target on Clarivate from $4.25 to $2.80 and set a “neutral” rating on the stock in a research report on Wednesday, March 4th. Five research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $3.22.

Clarivate Stock Performance

NYSE:CLVT opened at $2.54 on Monday. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of -12.07 and a beta of 1.37. The firm’s fifty day moving average price is $2.53 and its 200 day moving average price is $2.81. Clarivate PLC has a 1-year low of $1.66 and a 1-year high of $4.77.

Clarivate (NYSE:CLVT) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.04. The company had revenue of $585.50 million during the quarter, compared to the consensus estimate of $569.50 million. Clarivate had a negative net margin of 5.61% and a positive return on equity of 8.82%. Clarivate’s quarterly revenue was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.14 EPS. Clarivate has set its FY 2026 guidance at 0.700-0.800 EPS. On average, sell-side analysts expect that Clarivate PLC will post 0.65 EPS for the current year.

Clarivate Company Profile

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.